Danaher (DHR) Up 2% Since Last Earnings Report: Can It Continue?

Core Insights - Danaher Corporation's third-quarter 2025 adjusted earnings of $1.89 per share exceeded the Zacks Consensus Estimate of $1.71, marking a 10.5% year-over-year increase [3] - The company reported net sales of $6.05 billion, surpassing the consensus estimate of $6.00 billion, with a year-over-year growth of 4.5% [3] - The overall core sales increased by 3% year over year, with foreign-currency translations contributing positively by 1.5% [4] Segment Performance - Life Sciences segment revenues reached $1.79 billion, a 0.5% increase year over year, although core sales decreased by 1% [5] - Diagnostics segment revenues totaled $2.46 billion, up 4% year over year, with core sales increasing by 3.5% [6] - Biotechnology segment revenues were $1.80 billion, reflecting a 9% year-over-year increase, with core sales rising by 6.5% [7] Margin and Profitability - Danaher's cost of sales rose by 5.5% year over year to $2.53 billion, while gross profit increased by 3.6% to $3.52 billion, resulting in a gross margin of 58.2% [8] - Operating profit surged by 20.5% year over year to $1.15 billion, with the operating margin expanding to 19.1% from 16.5% [9] Balance Sheet and Cash Flow - At the end of the third quarter, Danaher had cash and equivalents of $1.53 billion, down from $2.08 billion at the end of 2024, while long-term debt increased to $16.8 billion [10] - The company generated net cash of $4.30 billion from operating activities in the first nine months of 2025, a decrease from $4.67 billion in the previous year [11] Future Outlook - For the fourth quarter, Danaher anticipates adjusted core sales from continuing operations to grow in the low single digits year over year, with adjusted earnings expected to be between $7.70 and $7.80 per share [12] - Estimates for the stock have trended downward, with a consensus estimate shift of -9.79% over the past month [13] Investment Scores - Danaher currently holds a subpar Growth Score of D and a Momentum Score of F, with an aggregate VGM Score of F, indicating it is in the bottom 40% for value investors [14]